1. Introduction {#sec1}
===============

Solitary fibrous tumors are rare mesenchymal neoplasms, considered a variant of hemangiopericytomas usually originates in the pleura; however, there have been reports of extrapleural origin (abdomen, retroperitoneum, upper extremities, orbit, cervix, meninges, mediastinum, parotid, nasal cavity, neck, etc.) \[[@B1]--[@B4]\]. The location is even more rare urogenital, and according to the literature, only 49 cases of solitary fibrous tumor of the kidney have been reported in the literature \[[@B5]\]. The origin of the majority of cases formed in the kidney is found in the renal capsule tissue or connective tissue interstitial peripelvis. Most cases presented with suspected renal cell neoplasms; however, morphologically, solitary fibrous tumors are characterized by the proliferation of spindle cells with little pattern in their architecture, and the final diagnosis was made with immunohistochemical findings that show staining for CD34 \[[@B6]--[@B9]\].

2. Case Report {#sec2}
==============

A 49 year old woman with no history of importance who enters the emergency room by 2-months of dyspnea at rest, associated with pleuritic chest pain on right chest, dry cough, no fever. The chest radiograph showed a right pleural effusion and multiple nodular lesions on the pleura, so we decided to perform a CT chest and abdomen in which evidenced free right pleural effusion occupying 80% of the right chest, at least two pleural masses with solid density that capture the contrast, multiple pulmonary nodules with soft tissue density in both lungs and left kidney mass. Carried left nephrectomy with suspected metastatic renal carcinoma, shows renal mass plus liver metastases which were resected. The analysis of the tumor presented as a first option versus solitary fibrous tumor angiomyolipoma. Immunohistochemical studies that showed cell reactivity with CD34, CD99, BCL-2, and vimentin are negative for HMB-45, AMS, CD68, cytokeratin cocktail, and S100, and the Ki67 is not assessable ([Figure 1](#fig1){ref-type="fig"}). This profile supports the histological diagnosis of solitary fibrous tumor with origin in the kidney.

We decided to start treatment with interferon a2b subcutaneous dose, extrapolating the cases of patients with solitary fibrous tumor of the pleura \[[@B19]\]. The dose was adjusted for flu symptoms and she is with stable disease at 23 months follow-up.

3. Discussion {#sec3}
=============

Solitary fibrous tumors are extremely rare tumors, arising mostly at the level of the pleura, and cases arising from the urogenital region are even more rare, with 49 cases reported so far in the literature. The histogenesis of this entity is still unknown, but recent studies suggest a primitive mesenchymal cells or level perivascular \[[@B11], [@B10]\].

The differential diagnosis of these cases includes sarcomatoid variant of renal carcinoma, angiomyolipoma, fibromas, and fibrosarcomas. [Table 1](#tab1){ref-type="table"} presents the cases so far published, reporting the primary source, and histologic variant outcomes.

These results show a relatively rare entity, with peak presentation in the fifth decade of life, arising mostly in the renal parenchyma unilaterally ([Table 2](#tab2){ref-type="table"}).

About 14% of patients have aggressive behavior where common management strategy is nephrectomy with complete resection of the lesions. The pathological findings that have been correlated with aggressive behavior are pleomorphism, increased cellularity and mitotic activity (\>4 mitosis/10 high-power fields), necrosis, hemorrhage, and atypical sites (parietal pleura, lung parenchyma) \[[@B12]\]. However, even the clinical behavior can not accurately predict the histopathological findings, as some cases with results suggesting benign disease may show aggressive behavior and vice versa, so it is necessary that these patients have an indefinite period of observation \[[@B13]--[@B18]\].

In relation to the management of this condition, there is as yet no prospective evaluation of any specific treatment modality; however, case reports and retrospective case series suggest that complete surgical resection and long-term followup are generally most recommended strategies. In cases such as the present, which present with metastatic disease, there is no clearly defined systemic therapy. Metastasectomy is thought to improve progression-free survival, but in many cases like this, this strategy is not feasible.

In case reports hemangiopericytomas, entity closely related to solitary fibrous tumors, has achieved stable disease with the use of interferon with or without thalidomide. So far, this is the first case reported in the literature in which benefit is demonstrated with the use of interferon in a patient with a malignant variant renal solitary fibrous tumor with metastatic disease, achieving stable disease for about 20 months.

Some authors suggest the use of antiangiogenic therapies (bevacizumab, sunitinib, pazopanib, etc.), based on the findings of high vascularity and a possible origin of pericytes at this entity \[[@B14]\]. The combination of bevacizumab associated with temozolomide is a potentially promising scheme for patients with solitary fibrous tumors. A series of 14 patients with solitary fibrous tumor unresectable or metastatic, were treated with temozolomide 150 mg/m2 orally on days 1--7 and days 15--21 and bevacizumab 5 mg/kg intravenously on days 8 and 22, with cycles every 28 days. In this study, 11 patients (79%) achieved partial response assessed by Choi criteria with 2 cases (14%) with stable disease. The median progression-free survival was 8.6 months \[[@B19], [@B18], [@B20]\].

![Immunohistochemical evidence CD34 positive cells (panel B), vimentin (panel C), and negative for S100 (panel D).](CRIM.ONCMED2013-564980.001){#fig1}

###### 

Summary of reported cases of renal SFT. (N.A. data not presented in the publication.)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case     Reference                                                           Age                           Sex    Localization                       Size (cms)                     Subtype     Followup (months)   Outcomes
  -------- ------------------------------------------------------------------- ----------------------------- ------ ---------------------------------- ------------------------------ ----------- ------------------- -----------------------------------
  1        Fain et al. J Urol Pathol 1996; 4: 227--238                         45                            F      Right kidney                       6                              Benign      8                   Tumor free

  2        Fain et al. J Urol Pathol 1996; 4: 227--238                         46                            F      Right kidney                       7,2                            Benign      33                  Tumor free

  3        Fain et al. J Urol Pathol 1996; 4: 227--238                         51                            M      Left kidney                        4,5                            Benign      2                   Tumor free

  4        Gelb et al. Am J Surg Pathol 1996; 20: 1288--1295                   48                            F      Right kidney                       3                              Benign      1                   Death from other cause Tumor free

  5        Fukunaga and Nikaido Histopathology 1997; 30: 451--456              33                            F      Right kidney                       3,5                            Benign      90                  Tumor free

  6        Fukunaga and Nikaido Histopathology 1997; 30: 451--456              36                            F      Left kidney                        2                              Benign      12                  Tumor free

  7        Hasegawa et al. \[[@B2]\]                                           64                            M      Kidney (laterality not reported)   4,5                            Benign      8                   Tumor free

  8        Leroy et al. Urol Int 2000; 65: 49--52                              66                            F      Right kidney                       9                              Benign      9                   Tumor free

  9        Morimitsu et al. APMIS 2000; 108: 617--625                          72                            F      Right kidney                       8                              Benign      10                  Tumor free

  10       Yazaki et al. Int J Urol 2001; 8: 504--508                          70                            M      Right kidney                       6                              Benign      N.A.                N.A.

  11       Wang et al. Am J Surg Pathol 2001; 25: 1194--1199                   41                            M      Right kidney                       14                             Benign      48                  Tumor free

  12       Wang et al. Am J Surg Pathol 2001; 25: 1194--1199                   72                            M      Right kidney                       13                             Benign      5                   Tumor free

  13       Cortes-Gutierrez et al. J Urol 2001; 166: 602                       28                            F      Left kidney                        15                             Benign      12                  Tumor free

  14       Magro et al. Pathol Res Pract 2002; 198: 37--43                     31                            F      Right kidney                       8,6                            Benign      8                   Tumor free

  15       Durand et al. Prog Urol 2003;13:491--494                            35                            M      Right kidney                       17                             Benign      6                   Tumor free

  16-17    Llarena Ibarguren et al. Arch Esp Urol 2003; 56: 835--840           51                            F      Bilateral                          25 (left)\                     Benign      N.A.                N.A.
                                                                                                                                                       2 (right)                                                      

  18       Bugel et al. Prog Urol 2003; 13: 1397--1401                         60                            F      Right kidney                       11                             Benign      48                  Tumor free

  19       Gres et al. Prog Urol 2004; 14: 65--66                              82                            M      Right kidney                       9                              Benign      13                  Tumor free

  20       Yamada et al. Pathol Int 2004; 54: 914--917                         59                            M      Left kidney                        6,8                            Benign      N.A.                N.A.

  21--27   Pierson et al. Mod Pathol 2005; 18: 159A                            Median (52,6) range 29--79)   N.A.   N.A.                               median (5,7), range 2,2--10)   Benign      N.A.                N.A.

  28       Kawagoe et al. Nishinihon J Urol 2005; 67: 568--571                 83                            F      Left kidney                        11                             Benign      20                  Tumor free

  29       Johnson et al. J Comput Assist Tomogr 2005; 29: 481--483            51                            F      Right kidney                       11                             Benign      N.A.                N.A.

  30       Yamaguchi et al. Urology 2005; 65: 175                              51                            F      Left kidney                        10                             Benign      N.A.                N.A.

  31       Kohl et al. Arch Pathol Lab Med 2006; 130: 117--119                 85                            F      Left kidney                        3,5                            Benign      N.A.                N.A.

  32       Koroku et al. Hinyokika Kiyo 2006; 52: 705--706                     18                            F      Left kidney                        3,2                            Benign      15                  Tumor free

  33       Provance / Ferrari et al. Clin Pediatr (Phila) 2006; 45: 871--873   4                             M      Right kidney                       8                              Benign      N.A.                N.A.

  34       Fine et al. \[[@B3]\]                                               76                            M      Left kidney                        12                             Malignant   4                   Persistent tumor

  35       Bozkurt et al. APMIS 2007; 115: 259--262                            51                            F      Left kidney                        4                              Benign      10                  Tumor free

  36       Znati et al. \[[@B11]\]                                             70                            M      Left kidney                        15                             Benign      6                   Tumor free

  37       Constantinidis et al. Can J Urol 2007; 14: 3583--3587               26                            M      Right kidney                       5                              Benign      6                   Tumor free

  38       Hirabayashi et al. Hinyokika Kiyo 2008; 54: 357--359                44                            F      Left kidney                        5,8                            Benign      28                  Tumor free

  39       Magro et al. \[[@B10]\]                                             34                            F      Left kidney                        9                              Malignant   15                  Tumor free

  40       Amano et al. Hinyokika Kiyo 2008; 54: 765--769                      67                            M      Left kidney                        7                              Benign      10                  Tumor free

  41       Yoneyama et al. Hinyokika Kiyo 2009; 55: 479--481                   76                            F      Right kidney                       2,2                            Benign      48                  Tumor free

  42       Hirano et al. \[[@B6]\]                                             75                            M      Left kidney                        4,5                            Benign      9                   Tumor free

  43       Taxa et al. Actas Urol Esp 2010; 34: 568--570                       39                            F      Left kidney                        2,5                            Benign      12                  Tumor free

  44       Yamaguchi et al. Hinyokika Kiyo 2010; 56: 435--438                  39                            F      Left kidney                        20                             Benign      6                   Tumor free

  45       Marzi et al. Minerva Urol Nefrol 2011; 63: 109--113                 72                            F      Left kidney                        19                             Malignant   N.A.                N.A.

  46       Hsieh et al. \[[@B8]\]                                              50                            F      Right kidney                       9                              Malignant   30                  Tumor free

  47       De Martino et al. \[[@B5]\]                                         68                            F      Left kidney                        7                              Malignant   5                   Death by the disease

  48       Caso actual                                                         49                            F      Left kidney                        9,8                            Malignant   23                  Stable disease
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Clinicopathologic features and outcomes of the 49 cases reported with solitary fibrous tumors of the kidney.

  ----------------------------- -------------
  Median age in years (range)   51 (4--85)
  Sex                            
   Male                         14
   Female                       28
   Unknown                      7
  Location                       
    Left kidney                 23
    Right kidney                17
    Bilateral                   1
    Unknown                     8
  Site                           
    Kidney                      33
    Renal capsule               6
    Peripelvis                  3
    Pelvis                      1
    Unknown                     6
  Medium size in cm (range)     7,6 (2--20)
  Histology                      
    Benign                      42
    Malignant                   7
  Treatment                      
    Tumor resection             2
    Nephrectomy                 41
    Unknown                     6
   Subcutaneous interferon      1
  Outcome                        
    No evidence of disease      25
    Metastasis                  4
    Unknown                     20
  ----------------------------- -------------
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